Format
Sort by
Items per page

Send to

Choose Destination

Best matches for agomelatine bipolar:

Search results

Items: 1 to 20 of 39

1.

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR.

Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. Review.

2.

Agomelatine-Related Shift to Mania in a Patient With Recurrent Depressive Disorder.

Kennel J, Baus C, Dogui R, Siebert S, Riemenschneider M.

Prim Care Companion CNS Disord. 2017 Oct 26;19(5). pii: 16l02079. doi: 10.4088/PCC.16l02079. No abstract available.

3.

Predicting early transition from sub-syndromal presentations to major mental disorders.

Cross SPM, Scott J, Hickie IB.

BJPsych Open. 2017 Sep 13;3(5):223-227. doi: 10.1192/bjpo.bp.117.004721. eCollection 2017 Sep.

4.

Fibromyalgia and bipolar disorder: extent of comorbidity and therapeutic implications.

Di Tommaso Morrison MC, Carinci F, Lessiani G, Spinas E, Kritas SK, Ronconi G, Caraffa A, Conti P.

J Biol Regul Homeost Agents. 2017 Jan-Mar;31(1):17-20. Review.

PMID:
28337866
5.

[Daily dynamics of time perception in bipolar II disorder patients with redarted or anxious depression].

Zimina SV, Kostyukova EG, Mosolov SN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(12):34-38. doi: 10.17116/jnevro201611612134-38. Russian.

PMID:
28139623
6.

[Agomelatine (valdoxan) in treatment of endogenous depression in day patient department].

Chernova EV, Kozhechkina OV, Ter-Israelyan AY, Medvedev VE.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10):43-46. doi: 10.17116/jnevro201611610143-46. Russian.

PMID:
27845315
7.

The relative contributions of psychiatric symptoms and psychotropic medications on the sleep-wake profile of young persons with anxiety, depression and bipolar disorders.

Robillard R, Oxley C, Hermens DF, White D, Wallis R, Naismith SL, Whitwell B, Southan J, Scott EM, Hickie IB.

Psychiatry Res. 2016 Sep 30;243:403-6. doi: 10.1016/j.psychres.2016.06.025. Epub 2016 Jun 17.

PMID:
27449011
8.

The bipolarity of light and dark: A review on Bipolar Disorder and circadian cycles.

Abreu T, Bragança M.

J Affect Disord. 2015 Oct 1;185:219-29. doi: 10.1016/j.jad.2015.07.017. Epub 2015 Jul 26. Review.

PMID:
26241867
9.

Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial.

Yatham LN, Vieta E, Goodwin GM, Bourin M, de Bodinat C, Laredo J, Calabrese J; Agomelatine Study Group.

Br J Psychiatry. 2016 Jan;208(1):78-86. doi: 10.1192/bjp.bp.114.147587. Epub 2015 May 21.

PMID:
25999335
10.

[A comparative study of different types of pharmacotherapy in treatment of depressive phase of bipolar II disorder].

Ushkalova AV, Kostyukova EG, Mosolov SN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(1 Pt 2):23-30. doi: 10.17116/jnevro20151151223-30. Russian.

PMID:
25909803
11.

The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms.

Perugi G, Quaranta G, Bucci N.

Expert Opin Investig Drugs. 2015 May;24(5):705-13. doi: 10.1517/13543784.2015.1021918. Epub 2015 Mar 1. Review.

PMID:
25727766
12.

Low Risk for Switch to Mania during Treatment with Sleep Promoting Antidepressants.

Wichniak A, Jarkiewicz M, Okruszek Ł, Wierzbicka A, Holka-Pokorska J, Rybakowski JK.

Pharmacopsychiatry. 2015 May;48(3):83-8. doi: 10.1055/s-0034-1396802. Epub 2015 Jan 19. Review.

PMID:
25599460
13.

Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.

De Berardis D, Fornaro M, Serroni N, Campanella D, Rapini G, Olivieri L, Srinivasan V, Iasevoli F, Tomasetti C, De Bartolomeis A, Valchera A, Perna G, Mazza M, Di Nicola M, Martinotti G, Di Giannantonio M.

Int J Mol Sci. 2015 Jan 5;16(1):1111-30. doi: 10.3390/ijms16011111. Review.

14.

Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine.

Boulle F, Massart R, Stragier E, Païzanis E, Zaidan L, Marday S, Gabriel C, Mocaer E, Mongeau R, Lanfumey L.

Transl Psychiatry. 2014 Nov 25;4:e485. doi: 10.1038/tp.2014.125.

16.

Agomelatine-associated manic switch in bipolar depression: a case report.

Thorpe M, Pannell J, Nance M.

Aust N Z J Psychiatry. 2014 Oct;48(10):958-9. doi: 10.1177/0004867414529339. Epub 2014 Mar 21. No abstract available.

PMID:
24658295
17.

Agomelatine in depression.

Smeraldi E, Delmonte D.

Expert Opin Drug Saf. 2013 Nov;12(6):873-80. doi: 10.1517/14740338.2013.828690. Epub 2013 Sep 16. Review.

PMID:
24033095
18.

Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study.

Fornaro M, McCarthy MJ, De Berardis D, De Pasquale C, Tabaton M, Martino M, Colicchio S, Cattaneo CI, D'Angelo E, Fornaro P.

Neuropsychiatr Dis Treat. 2013;9:243-51. doi: 10.2147/NDT.S41557. Epub 2013 Feb 15.

19.

Biological rhythms and melatonin in mood disorders and their treatments.

Lanfumey L, Mongeau R, Hamon M.

Pharmacol Ther. 2013 May;138(2):176-84. doi: 10.1016/j.pharmthera.2013.01.005. Epub 2013 Jan 21. Review.

PMID:
23348014
20.

[A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder].

Tiuvina NA, Smirnova VN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(11 Pt 2):53-60. Russian.

PMID:
23257757

Supplemental Content

Loading ...
Support Center